Action NEEDED by February 9
Right now the Centers for Medicare and Medicaid Services is drafting guidelines for their Coverage with Evidence Development in the use of the new Alzheimer’s drug, aducanumab, excluding people with Down syndrome and other intellectual and developmental disabilities (I/DD). A quick comment from you could change the course of Hope’s life! Please help.